Histidine

證據等級: L5

預測適應症: 10 個

Histidine: From Essential Amino Acid to Gastroparesis

One-Sentence Summary

Histidine is an essential amino acid involved in protein biosynthesis and metabolic regulation, with no formally registered therapeutic indications in Singapore. The TxGNN model predicts it may be effective for Gastroparesis, with 0 clinical trials and 0 publications currently directly supporting this indication. This prediction is based entirely on computational modeling, placing it at the lowest evidence tier.

Quick Overview

Item	Content
Original Indication	No registered therapeutic indications
Predicted New Indication	Gastroparesis
TxGNN Prediction Score	99.55%
Evidence Level	L5
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Histidine as a therapeutic agent. Based on established biochemistry, Histidine is an essential amino acid that serves as the direct metabolic precursor to histamine via the enzyme L-histidine decarboxylase (HDC). Histamine acts on H1, H2, H3, and H4 receptors, which are distributed throughout the gastrointestinal tract and modulate gastric acid secretion, gastric motility, and mucosal function.

Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction, often accompanied by nausea, vomiting, and postprandial bloating. H2 receptors expressed on gastric parietal cells and enteric neurons influence both acid secretion and gastric contractility. The TxGNN model's prediction likely draws on this histidine → histamine → H2 receptor axis as a plausible mechanistic bridge. In principle, modulation of this pathway could affect the gastrointestinal neuromuscular coordination involved in gastroparesis.

However, this mechanistic connection is entirely speculative. No preclinical studies, animal models, or clinical investigations have directly tested whether histidine supplementation meaningfully alters gastric motility. Moreover, the net direction of any histidine-mediated effect is unclear — increased histamine production could theoretically either promote or impair gastric emptying depending on receptor subtype and tissue context. This prediction should be treated as a computational hypothesis requiring experimental validation before any further development consideration.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Histidine has no registered pharmaceutical products in Singapore (0 licenses on record).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction rests entirely on computational inference (L5 evidence) with no supporting clinical trials, published studies, or regulatory precedent in any jurisdiction. The proposed histidine → histamine → gastric motility pathway is biologically plausible but unvalidated, and Singapore has no approved Histidine-containing products against which to benchmark safety or dosing.

To proceed, the following is needed:

Retrieval of full mechanism of action data from DrugBank (DB00117) to characterize histidine's known pharmacological effects
Targeted literature search for preclinical evidence of histidine's effect on gastric emptying or enteric neuromuscular function
In vitro or animal model studies examining whether histidine supplementation modulates gastric motility via the HDC-histamine-H2 receptor axis
Safety profile review: package insert data, acceptable daily intake levels, and any known GI adverse effects at pharmacological doses
Regulatory landscape review: identify whether any jurisdiction has evaluated histidine as a pharmacological agent (distinct from nutritional supplementation) for GI indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.